J. Reubi

发表

The VPAC2 Receptor Is Essential for Circadian Function in the Mouse Suprachiasmatic Nuclei

E. Maywood, M. Hastings, J. Kelly, 2002, Cell.

The role of somatostatin and its analogs in the diagnosis and treatment of tumors.

E. Krenning, S. Lamberts, J. Reubi, 1991, Endocrine reviews.

Peptide receptors as molecular targets for cancer diagnosis and therapy.

J. Reubi, 2003, Endocrine reviews.

Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study.

J. Reubi, B. Nock, T. Maina, 2005, Journal of medicinal chemistry.

Comparative biodistribution of 12 111In-labelled gastrin/CCK2 receptor-targeting peptides

W. Oyen, A. Eek, O. Boerman, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

Localization of 99mTc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses

E. Krenning, M. de Jong, J. Reubi, 2019, Pharmaceuticals.

Progesterone, oestradiol, somatostatin and epidermal growth factor receptors on human meningiomas and their CT characteristics.

J. Foekens, C. Avezaat, S. Lamberts, 1991, European journal of cancer.

Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.

J C Reubi, J. Reubi, R. Markwalder, 1999, Cancer research.

Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast.

J C Reubi, J. Reubi, M. Gugger, 1999, The American journal of pathology.

Bombesin Receptors in Distinct Tissue Compartments of Human Pancreatic Diseases

H. Friess, J. Reubi, A. Fleischmann, 2000, Laboratory Investigation.

Bombesin Receptor Subtypes in Human Cancers: Detection with the Universal Radioligand 125I-[d-TYR6, β-ALA11, PHE13, NLE14] Bombesin(6–14)

J. Reubi, M. Gugger, S. Wenger, 2002 .

Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA

A. Nunn, J. Reubi, K. Linder, 2006, European Journal of Nuclear Medicine and Molecular Imaging.

177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.

Thangavel Arunachalam, Luciano Lattuada, A. Nunn, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours

M. Eisenhut, J. Reubi, Hanwen Zhang, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid–Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission Tomography, and Therapeutic Radionuclides

S. Kneifel, F. Forrer, J. Reubi, 2009, Clinical Cancer Research.

Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men

W. Schultze‐Seemann, P. Meyer, W. Weber, 2014, Theranostics.

N-Terminal Modifications Improve the Receptor Affinity and Pharmacokinetics of Radiolabeled Peptidic Gastrin-Releasing Peptide Receptor Antagonists: Examples of 68Ga- and 64Cu-Labeled Peptides for PET Imaging

J. Reubi, F. Buchegger, R. Mansi, 2014, The Journal of Nuclear Medicine.

PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists.

J. Reubi, R. Mansi, B. Waser, 2014, Nuclear medicine and biology.

Evaluation of three different families of bombesin receptor radioantagonists for targeted imaging and therapy of gastrin releasing peptide receptor (GRP-R) positive tumors.

J. Reubi, R. Mansi, H. Maecke, 2015, Journal of medicinal chemistry.

Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer

E. Krenning, M. Jong, J. Erion, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Autoradiographic mapping of somatostatin receptors in the rat central nervous system and pituitary

J. Reubi, R. Maurer, 1985, Neuroscience.

Novel Positron Emission Tomography/Computed Tomography of Diffuse Parenchymal Lung Disease Combining a Labeled Somatostatin Receptor Analogue and 2-Deoxy-2 [18F] Fluoro-D-Glucose

R. Shortman, A. Groves, I. Kayani, 2012, Molecular imaging.

Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis.

D. Le Guludec, J. Reubi, B. Crestani, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Increased Uptake of 111 In-Octreotide in Idiopathic Pulmonary Fibrosis

J. Reubi, B. Crestani, R. Lebtahi, 2006 .

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients

E. Christ, N. Pellegata, J. Reubi, 2019, Endocrine connections.

A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas

J. Beck, E. Christ, J. Reubi, 2017, Neuroendocrinology.

Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers

J. Rivier, J. Reubi, B. Waser, 2011, EJNMMI research.

Somatostatin Receptors

J. Reubi, C. B. Srikant, Y. Patel, 1997, Trends in Endocrinology & Metabolism.

closo-borane conjugated regulatory peptides retain high biological affinity: synthesis of closo-borane conjugated Tyr(3)-octreotate derivatives for BNCT.

J. Reubi, B. Waser, F. Roesch, 2008, Bioconjugate chemistry.

Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P

S. Kneifel, S. Hofer, A. Merlo, 2006, Clinical Cancer Research.

Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer.

P. Meyer, J. Reubi, B. Waser, 2015, Molecular pharmaceutics.

Targeted Radiotherapy of Prostate Cancer with a Gastrin-Releasing Peptide Receptor Antagonist Is Effective as Monotherapy and in Combination with Rapamycin

W. Weber, J. Reubi, Rebecca A. Dumont, 2013, The Journal of Nuclear Medicine.

Evolution of Bombesin Conjugates for Targeted PET Imaging of Tumors

M. Honer, J. Reubi, D. Thorek, 2012, PloS one.

Bombesin Antagonist–Based Radioligands for Translational Nuclear Imaging of Gastrin-Releasing Peptide Receptor–Positive Tumors

F. Forrer, J. Reubi, G. Nicolas, 2011, The Journal of Nuclear Medicine.

Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease.

H. Friess, M. Büchler, M. Korc, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours

M. Walter, J. Müller-Brand, J. Reubi, 2008, European Journal of Nuclear Medicine and Molecular Imaging.

Stereochemistry of amino acid spacers determines the pharmacokinetics of (111)In-DOTA-minigastrin analogues for targeting the CCK2/gastrin receptor.

J. Reubi, R. Mansi, B. Waser, 2015, Bioconjugate chemistry.

Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607

M. Jong, W. Breeman, J. Reubi, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607

M. Ocak, G. Morelli, A. Eek, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor.

R. Baum, J. Reubi, R. Mansi, 2011, Journal of medicinal chemistry.

Preclinical Evaluation of Radiolabeled DOTA-Derivatized Cyclic Minigastrin Analogs for Targeting Cholecystokinin Receptor Expressing Malignancies

C. Decristoforo, J. Reubi, P. Laverman, 2012, Molecular Imaging and Biology.

Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.

J. Charboneau, C. Reading, D. Nagorney, 1990, Cancer research.

Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach.

H. Friess, J. Reubi, B. Waser, 1997, Gastroenterology.

Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo

J. Erion, J. Reubi, J. Bugaj, 1998, European Journal of Nuclear Medicine.

Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy.

R. Valkema, B. Bernard, E. Krenning, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma

E. Krenning, J. Erion, M. de Jong, 2000, European Journal of Nuclear Medicine.

CCK receptors in human neuroendocrine tumors: Clinical implications

J. Reubi, 2001, Scandinavian journal of clinical and laboratory investigation. Supplementum.

NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.

J. Reubi, Hanwen Zhang, H. Mäcke, 2002, Bioconjugate chemistry.

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals

B. Bernard, E. Krenning, M. Jong, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Octreotide and Nonendocrine Tumors: Basic Knowledge and Therapeutic Potential

J. Reubi, 1996 .

Somatostatin-receptor imaging in the localization of endocrine tumors.

E. Krenning, S. Lamberts, J. Reubi, 1990, The New England journal of medicine.

Guiding principles applied in the design of GPCR-selective hypothalamic hormone agonists and antagonists

R. Riek, W. Vale, J. Rivier, 2006 .

Glutamine as precursor for the GABA and glutamate trasmitter pools

M. Cuénod, J. Reubi, C. V. D. Berg, 1978, Neuroscience Letters.

Neuropeptide Y acts within the rat testis to inhibit testosterone secretion

C. Rivier, J. Reubi, C. Allen, 2011, Neuropeptides.

Release and distribution of endogenous 5-HT in rat substantia nigra

J. Reubi, P. Emson, 1978, Brain Research.

Identification of somatostatin receptors in human small cell lung carcinoma

R. Ginsberg, R. Kerbel, K. Kovacs, 1990, Cancer.

Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

J. Reubi, B. Waser, H. Mäcke, 2000, European Journal of Nuclear Medicine.

Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

J. Laissue, J. Reubi, B. Waser, 2001, European Journal of Nuclear Medicine.

Chapter 17 - Somatostatin

E. Krenning, S. Lamberts, J. Reubi, 1997 .

Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog

E. Krenning, S. Lamberts, J. Reubi, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

Clinical applications of somatostatin analogs

E. Krenning, S. Lamberts, J. Reubi, 1990, Trends in Endocrinology & Metabolism.

Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs.

E. Krenning, S. Lamberts, J. Reubi, 1990, Metabolism: clinical and experimental.

The clinical use of somatostatin analogues in the treatment of cancer.

J. Klijn, E. Krenning, S. Lamberts, 1990, Bailliere's clinical endocrinology and metabolism.

Potential role of somatostatin analogues in the treatment of cancer

S. Lamberts, J. Reubi, J. Koper, 1987, European journal of clinical investigation.

Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours

E. Krenning, B. Wiedenmann, R. Arnold, 2005 .

Characterization of a novel five-transmembrane domain cholecystokinin-2 receptor splice variant identified in human tumors

J. Reubi, B. Waser, C. Escrieut, 2012, Molecular and Cellular Endocrinology.

The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.

J. Charboneau, L. Kvols, J. Rubin, 1992, The Yale journal of biology and medicine.

Glucagon-Like Peptide-1 Versus Somatostatin Receptor Targeting Reveals 2 Distinct Forms of Malignant Insulinomas

P. Ell, F. Forrer, E. Christ, 2011, The Journal of Nuclear Medicine.

First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible

W. Weber, J. Rivier, J. Reubi, 2011, The Journal of Nuclear Medicine.

A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome.

E. Krenning, S. Lamberts, J. Reubi, 1994, The Journal of clinical endocrinology and metabolism.

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

R. Baum, J. Reubi, Hanwen Zhang, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Somatostatin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

D. Hoyer, S. Schulz, S. Melmed, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications

W. Weber, J. Rivier, J. Reubi, 2012, The Journal of Nuclear Medicine.

Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment

J. Reubi, H. Maecke, 2011, The Journal of Nuclear Medicine.

Makes the Difference

W. Weber, J. Reubi, R. Mansi, 2011 .

Distribution pattern of 68Ga-DOTATATE in disease-free patients

D. Visvikis, I. Kayani, S. Gacinovic, 2010, Nuclear medicine communications.

Radiolabeled Bicyclic Somatostatin-Based Analogs: A Novel Class of Potential Radiotracers for SPECT/PET of Neuroendocrine Tumors

J. Reubi, G. Nicolas, H. Maecke, 2010, The Journal of Nuclear Medicine.

68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5

J. Reubi, M. Hofmann, D. Wild, 2005, European Journal of Nuclear Medicine and Molecular Imaging.

Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.

S. Schulz, M. Culler, J. Rivier, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy.

H. Bruining, E. Krenning, S. Lamberts, 1990, The Journal of clinical endocrinology and metabolism.

Erratum to: Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

J. Laissue, J. Reubi, B. Waser, 2001, European Journal of Nuclear Medicine.

Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging.

J C Reubi, J. Reubi, J. Reubi, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Preclinical evaluation of somatostatin analogs bearing two macrocyclic chelators for high specific activity labeling with radiometals

J. Reubi, C. Waldherr, B. Waser, 2007 .

Synthesis and Evaluation of Bombesin Derivatives on the Basis of Pan-Bombesin Peptides Labeled with Indium-111, Lutetium-177, and Yttrium-90 for Targeting Bombesin Receptor-Expressing Tumors

J. Reubi, Hanwen Zhang, C. Waldherr, 2004, Cancer Research.

Biodistribution and catabolism of (18)F-labeled neurotensin(8-13) analogs.

M. Scheunemann, D. Zips, R. Bergmann, 2002, Nuclear medicine and biology.

Bombesin Receptor Subtypes in Human Cancers: Detection with the Universal Radioligand I-[ Bombesin(6 –14)

J. Reubi, M. Gugger, S. Wenger, 2002 .

Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14).

J. Reubi, M. Gugger, S. Wenger, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Localization and characterization of neuropeptide receptors in human colon

J. Reubi, M. Rettenbacher, 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

Y1-Mediated Effect of Neuropeptide Y in Cancer

J. Reubi, M. Gugger, B. Waser, 2001 .

In Vitro Evaluation of VIP/PACAP Receptors in Healthy and Diseased Human Tissues: Clinical Implications

J. Reubi, 2000, Annals of the New York Academy of Sciences.

Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours

B. Wiedenmann, J. Reubi, S. Faiss, 2000, European Journal of Nuclear Medicine.

Regulatory peptide receptors in human hepatocellular carcinomas

P. Neuhaus, B. Wiedenmann, J. Reubi, 1999, Gut.

Immunohistochemical localization of somatostatin receptors sst2A in human tumors.

J. Laissue, A. Kappeler, J. Reubi, 1998, The American journal of pathology.

A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors.

J. Rivier, J. Reubi, B. Waser, 1998, European journal of pharmacology.

Relevance of somatostatin receptors and other peptide receptors in pathology

J. Reubi, 1997, Endocrine pathology.

Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.

T. Moody, M. Birrer, I. Gozes, 1996, Cancer research.

A case of antibody formation against octreotide visualized with 111In‐octreotide scintigraphy

E. Krenning, S. Lamberts, J. Reubi, 1993, Clinical endocrinology.

The role of peptides and their receptors as tumor markers.

J. Reubi, 1993, Endocrinology and metabolism clinics of North America.

Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses.

J. Reubi, P. Heitz, A. Landolt, 1987, The Journal of clinical endocrinology and metabolism.

in vitro and in vivo detection of somatostatin receptors in human malignant lymphomas

E. Krenning, S. Lamberts, J. Reubi, 1992, International journal of cancer.

In vitro detection of somatostatin receptors in human tumors.

L. Kvols, E. Krenning, J. Reubi, 1992, Metabolism: clinical and experimental.

Does Somatostatin or Gastric Inhibitory Peptide Receptor Expression Correlate with Tumor Grade and Stage in Gut Neuroendocrine Tumors?

J. Reubi, B. Waser, M. Körner, 2015, Neuroendocrinology.

Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy.

R. Valkema, E. Krenning, C. V. van Eijck, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Somatostatin receptors and somatostatin content in medullary thyroid carcinomas.

B. Franc, J. Reubi, R. Cohen, 1991, Laboratory investigation; a journal of technical methods and pathology.

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

E. P. Krenning, W. H. Bakker, A. E. M. Reijs, 1993, European Journal of Nuclear Medicine.

[DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.

E. Krenning, M. de Jong, J. Reubi, 2014, European journal of medicinal chemistry.

[111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors.

E. Krenning, M. de Jong, J. Reubi, 2014, Journal of medicinal chemistry.

A rare case of a large spinal meningioma with mediastinal extension and malignant behavior classified histologically as benign.

A. Raabe, N. Cihoric, J. Reubi, 2013, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study

E. Krenning, M. de Jong, J. Reubi, 2012, EJNMMI Research.

111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy

B. Bernard, E. Krenning, M. Jong, 2005, European Journal of Nuclear Medicine and Molecular Imaging.

The value of octreotide scintigraphy in patients with lung cancer

E. Krenning, J. Laissue, S. Lamberts, 1994, European Journal of Nuclear Medicine.

Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide.

H. V. van Boven, R. Valkema, E. Krenning, 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.

E. Krenning, S. Lamberts, W. Breeman, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

In vitro detection of somatostatin receptors in human tumors.

L. Kvols, E. Krenning, J. Reubi, 1992, Digestion.

Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue.

J. Laissue, J. Reubi, U. Horisberger, 1992, Gastroenterology.

High incidence of somatostatin receptors in human meningiomas: biochemical characterization.

J. Foekens, J. Klijn, M. Blankenstein, 1986, The Journal of clinical endocrinology and metabolism.

Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth.

C. Avezaat, S. Lamberts, C. Kohler, 1992, The Journal of clinical endocrinology and metabolism.

Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro.

E. Krenning, S. Lamberts, T. D. de Bruin, 1992, The Journal of clinical endocrinology and metabolism.

Somatostatin receptors in human renal cell carcinomas.

L. Kvols, J. Reubi, J. Reubi, 1992, Cancer research.

The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status.

J. Reubi, A. Landolt, 1989, The Journal of clinical endocrinology and metabolism.

Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system.

J. Reubi, J. Koper, S. Lamberts, 1987, Cancer research.

Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications

E. Krenning, J. Laissue, S. Lamberts, 1992, The Journal of Steroid Biochemistry and Molecular Biology.

In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man.

T. Visser, E. Krenning, S. Lamberts, 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

In vivo somatostatin receptor imaging in medullary thyroid carcinoma.

E. Krenning, S. Lamberts, J. Reubi, 1993, The Journal of clinical endocrinology and metabolism.

Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors.

J. Reubi, J. Koper, U. Horisberger, 1989, The American journal of pathology.

Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals.

J. Klijn, T. Visser, E. Krenning, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Somatostatin receptors are present in small‐cell but not in non‐small‐cell primary lung carcinomas: Relationship to EGF‐receptors

J. Reubi, B. Waser, V. Macaulay, 1990, International journal of cancer.

Somatostatin receptor imaging of endocrine gastrointestinal tumors.

E. Krenning, S. Lamberts, J. Reubi, 1992, Schweizerische medizinische Wochenschrift.

In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats.

T. Visser, E. Krenning, M. Jong, 1991, Life sciences.

Carcinoid of the pancreas.

M. Büchler, C. Maurer, J. Reubi, 1997, Digestion.

Carcinoid of the pancreas: clinical characteristics and morphological features.

H. Friess, M. Büchler, C. Maurer, 1996, European journal of cancer.

SST3-selective potent peptidic somatostatin receptor antagonists.

J. Rivier, J. Reubi, B. Waser, 2000, Proceedings of the National Academy of Sciences of the United States of America.

What is a false-positive somatostatin receptor scintigraphy?

J. Reubi, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Approaches to Multireceptor Targeting: Hybrid Radioligands, Radioligand Cocktails, and Sequential Radioligand Applications

J. Reubi, H. Maecke, 2017, The Journal of Nuclear Medicine.

Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and -2 knockout mice.

J. Reubi, G. Zoidl, B. Waser, 2006, American journal of physiology. Gastrointestinal and liver physiology.

68Ga-exendin-4 PET/CT detects insulinomas in patients with endogenous hyperinsulinemic hypoglycemia in MEN-1.

P. Chanson, F. Pattou, E. Christ, 2019, The Journal of clinical endocrinology and metabolism.

Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma.

L. Miller, B. Wiedenmann, J. Reubi, 2006, Journal of hepatology.

Somatostatin-receptor scintigraphy in primary breast cancer

J. Jeekel, E. Krenning, J. Lindemans, 1994, The Lancet.

Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors

G. Christofori, C. Mamot, C. Rochlitz, 2014, EJNMMI Research.

Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors.

L. Kvols, M. Brown, M. O’Connor, 1993, Radiology.

A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors.

J. Reubi, B. Waser, H. Mäcke, 2002, European journal of pharmacology.

MINI-REVIEWS AND PERSPECTIVES Gastrin in Gastrointestinal Diseases

J. Reubi, D. Fourmy, V. Gigoux, 2011 .

Gastrin in gastrointestinal diseases.

J. Reubi, D. Fourmy, V. Gigoux, 2011, Gastroenterology.

[99mTc]Demotate 2 in the detection of sst2-positive tumours: a preclinical comparison with [111In]DOTA-tate

B. Bernard, E. Krenning, M. Jong, 2006, European Journal of Nuclear Medicine and Molecular Imaging.

New sst4/5-selective somatostatin peptidomimetics based on a constrained tryptophan scaffold.

J. Reubi, D. Tourwé, R. Cescato, 2007, Journal of medicinal chemistry.

Multiple actions of somatostatin in neoplastic disease.

J. Laissue, J. Reubi, 1995, Trends in pharmacological sciences.

Comparison of Somatostatin Receptor Expression in Human Gliomas and Medulloblastomas

C. Daumas-Duport, Z. Csaba, J. Reubi, 2002, Journal of neuroendocrinology.

Distinct topographical localisation of two somatostatin receptor subpopulations in the human cortex

J. Palacios, A. Probst, J. Reubi, 1987, Brain Research.

Metastatic carcinoid tumors and the malignant carcinoid syndrome.

L. Kvols, J. Reubi, 1993, Acta oncologica.

Receptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin Analogs

J. Rivier, J. Reubi, R. Cescato, 2005, Molecular Pharmacology.

CHAPTER 154 – Somatostatin

J. Reubi, M. Gugger, 2006 .

In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue.

E. Krenning, J. Laissue, J. Reubi, 1993, Blood.

Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis.

E. Krenning, S. Lamberts, J. Reubi, 1994, Arthritis and rheumatism.

Somatostatin receptors in human endocrine tumors.

J. Klijn, J. Reubi, K. von Werder, 1987, Cancer research.

Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion.

H. Bruining, E. Krenning, H. Pols, 1994, The American journal of medicine.

In vitro and in vivo detection of somatostatin receptors in human malignant tissues.

L. Kvols, E. Krenning, J. Reubi, 1991, Acta oncologica.

[99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging

G. Loudos, E. Chiotellis, J. Reubi, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro‐intestinal adenocarcinoma samples: Where are they really located?

J. Laissue, J. Reubi, B. Waser, 1999, International journal of cancer.

Somatostatin binding sites in human leptomeninx

J. Reubi, S. Lamberts, R. Maurer, 1986, Neuroscience Letters.

Neuropeptide Y Receptors in Primary Human Brain Tumors: Overexpression in High-Grade Tumors

J. Reubi, M. Körner, M. Körner, 2008, Journal of neuropathology and experimental neurology.

Receptors in Tumors of the Human Central Nervous System Distribution and Biochemical Characterization of Somatostatin

J. Reubi, S. Lamberts, R. Maurer, 2006 .

Expression of Somatostatin Receptors in Normal, Inflamed, and Neoplastic Human Gastrointestinal Tissues

J. Laissue, J. Reubi, U. Horisberger, 1994, Annals of the New York Academy of Sciences.

Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization.

G. Mengod, J. Reubi, B. Waser, 1994, Cancer research.

Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease.

L. Mazzucchelli, J. Laissue, J. Reubi, 1994, Gastroenterology.

Somatostatin receptors in the gastrointestinal tract in health and disease.

J. Reubi, 1992, The Yale journal of biology and medicine.

Differential effects of somatostatin on adenylate cyclase as functional correlate for different brain somatostatin receptor subpopulations

J. Reubi, R. Markstein, K. A. Stöckli, 1989, Neuroscience Letters.

Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors.

J. Reubi, S. Lamberts, W. Häcki, 1987, The Journal of clinical endocrinology and metabolism.

Somatostatin receptors in rat hippocampus: Localization to intrinsic neurons

J. Palacios, J. Reubi, R. Maurer, 1986, Neuroscience Letters.

Different ionic requirements for somatostatin receptor subpopulations in the brain

J. Reubi, R. Maurer, 1986, Regulatory Peptides.

High affinity binding sites for a somatostatin-28 analog in rat brain.

W. Vale, J. Rivier, J. Reubi, 1981, Life sciences.

High affinity binding sites for somatostatin to rat pituitary.

W. Vale, J. Rivier, J. Reubi, 1982, Biochemical and biophysical research communications.

Specific high affinity binding sites for somatostatin-28 on pancreatic beta-cells: differences with brain somatostatin receptors.

W. Vale, J. Rivier, J. Reubi, 1982, Endocrinology.

Expression of Somatostatin Receptors in Human Tissues in Health and Disease

J. Reubi, B. Waser, J. Schaer, 2004 .

Evidence for two somatostatin-14 receptor types in rat brain cortex

J. Reubi, 1984, Neuroscience Letters.

Brain somatostatin receptor subpopulation visualized by autoradiography

J. Reubi, R. Maurer, 1985, Brain Research.

Lack of evidence for autocrine feedback regulation by somatostatin in somatostatin receptor-containing meningiomas.

G. Mengod, J. Reubi, U. Horisberger, 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Somatostatin and Alzheimer's disease: a hypothesis

J. Reubi, J. Palacios, 1986, Journal of Neurology.

Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.

O. Gratzl, A. Merlo, J. Reubi, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Locoregional Regulatory Peptide Receptor Targeting with the Diffusible Somatostatin Analogue 90 Y-Labeled

O. Gratzl, A. Merlo, J. Reubi, 1999 .

Expression of functional neurokinin-1 receptors in regenerative glands during gastric wound healing in rodents.

J. Reubi, B. Waser, A. Schmassmann, 2004, Gastroenterology.

Substance‐P receptors in human primary neoplasms: Tumoral and vascular localization

J. Laissue, J. Reubi, U. Horisberger, 1995, International journal of cancer.

High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor‐host interaction?

J. Laissue, J. Reubi, U. Horisberger, 1994, International journal of cancer.

Distribution of somatostatin receptors in normal and tumor tissue.

L. Kvols, E. Krenning, J. Reubi, 1990, Metabolism: clinical and experimental.

In vivo mitogenic effects of estradiol on colon cancers: Role of gastrin and gastrin receptors

J. Reubi, P. Singh, G. Rajakumar, 1993, The Journal of Steroid Biochemistry and Molecular Biology.

Specific binding of cholecystokinin, estradiol and somatostatin to human pancreatic cancer xenografts

G. Poston, J. Reubi, Pomila Singh, 1991, The Journal of Steroid Biochemistry and Molecular Biology.

N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo.

M. Schwaiger, J. Reubi, H. Wester, 2005, Journal of medicinal chemistry.

Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study

W. Weber, J. Rivier, J. Reubi, 2014, The Journal of Nuclear Medicine.

Evaluation of 177Lu-DOTA-sst2 Antagonist Versus 177Lu-DOTA-sst2 Agonist Binding in Human Cancers In Vitro

J. Reubi, B. Waser, R. Cescato, 2011, The Journal of Nuclear Medicine.

The Glucose-Dependent Insulinotropic Polypeptide Receptor: A Novel Target for Neuroendocrine Tumor Imaging—First Preclinical Studies

J. Reubi, B. Waser, D. Fourmy, 2014, The Journal of Nuclear Medicine.

Early over‐expression of GRP receptors in prostatic carcinogenesis

J. Reubi, B. Waser, M. Körner, 2014, The Prostate.

Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma

E. Christ, J. Reubi, J. Komor, 2014, Pituitary.

Cholecystokinin-B/gastrin receptors enhance wound healing in the rat gastric mucosa.

J. Reubi, A. Schmassmann, 2000, The Journal of clinical investigation.

Illuminating somatostatin analog action at neuroendocrine tumor receptors.

J. Reubi, A. Schonbrunn, 2013, Trends in pharmacological sciences.

Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets.

J. Laissue, A. Kappeler, J. Reubi, 1998, The Journal of clinical endocrinology and metabolism.

Release of exogenous glycine in the pigeon optic tectum during stimulation of a midbrain nucleus

M. Cuénod, J. Reubi, 1976, Brain Research.

Glucagon-like peptide-1 (GLP-1) receptors are not overexpressed in pancreatic islets from patients with severe hyperinsulinaemic hypoglycaemia following gastric bypass

M. Patti, A. Goldfine, M. Callery, 2010, Diabetologia.

GLP-2 receptors in human disease: High expression in gastrointestinal stromal tumors and Crohn’s disease

J. Reubi, M. Körner, R. Rehmann, 2012, Molecular and Cellular Endocrinology.

Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis.

E. Krenning, J. Laissue, J. Reubi, 1994, European journal of pharmacology.

High density of somatostatin receptors in pituitary tumors from acromegalic patients.

J. Reubi, A. Landolt, 1984, The Journal of clinical endocrinology and metabolism.

Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin.

J. Reubi, J. Vonderscher, R. Maurer, 1986, Scandinavian journal of gastroenterology. Supplement.

Somatostatin receptors in the adrenal

J. Reubi, R. Maurer, 1986, Molecular and Cellular Endocrinology.

VASOACTIVE INTESTINAL PEPTIDE PRODUCING TUMOUR CONTAINS HIGH DENSITY OF SOMATOSTATIN RECEPTORS

J. Reubi, P. Heitz, K. Gyr, 1987, The Lancet.

Evaluation of somatostatin biosynthesis, somatostatin receptors and tumor growth in murine medullary thyroid carcinoma.

J. Reubi, M. Moukhtar, E. Pidoux, 1994, European journal of endocrinology.

GABA-specific presynaptic dendrites in pigeon optic tectum: a high resolution autoradiographic study

S. Hunt, M. Cuénod, P. Streit, 1978, Brain Research.

Somatostatin and Other Peptide Receptors as Tools for Tumor Diagnosis and Treatment

J. Reubi, 2004, Neuroendocrinology.

Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydration chemistry.

M. Schwaiger, J. Reubi, H. Wester, 2005, Bioconjugate chemistry.

Incretin Receptors in Non-Neoplastic and Neoplastic Thyroid C Cells in Rodents and Humans: Relevance for Incretin-Based Diabetes Therapy

N. Pellegata, J. Reubi, B. Waser, 2011, Neuroendocrinology.

Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours.

F. Forrer, J. Reubi, R. Mansi, 2010, Chemistry.

Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates.

M. Schwaiger, R. Senekowitsch-Schmidtke, J. Reubi, 2002, Bioconjugate chemistry.

Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics

M. Schwaiger, K. Scheidhauer, J. Reubi, 2001, European Journal of Nuclear Medicine and Molecular Imaging.

Central nervous system-mediated growth inhibition of a rat prostate carcinoma by an opioid.

J. Reubi, 1985, The Journal of endocrinology.

Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a.

J. Reubi, S. Lamberts, J. Zuiderwijk, 1986, Endocrinology.

The Use of Sandostatin® in Insulinomas. The Relation Between In Vivo Responses, the Presence of Somatostatin Receptors and the Development of Tachyphylaxis

S. Lamberts, J. Reubi, 1989 .

High Expression of Neuropeptide Y Receptors in Tumors of the Human Adrenal Gland and Extra-Adrenal Paraganglia

J. Reubi, B. Waser, M. Körner, 2004, Clinical Cancer Research.

Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers

P. Meyer, J. Reubi, R. Mansi, 2016, The Journal of Nuclear Medicine.

Approaches to improve the pharmacokinetics of radiolabeled GLP-1 receptor ligands using antagonistic tracers

P. Meyer, J. Reubi, R. Mansi, 2016 .

Highly Efficient In Vivo Agonist-Induced Internalization of sst2 Receptors in Somatostatin Target Tissues

J. Reubi, B. Waser, H. Maecke, 2009, Journal of Nuclear Medicine.

Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs.

J. Reubi, Hanwen Zhang, B. Nock, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model ( 213 Bi-DOTA-PESIN and

J. Reubi, Hanwen Zhang, F. Bruchertseifer, 2011 .

Study of a Primary Gastrinoma in the Common Hepatic Duct – A Case Report

H. Friess, M. Büchler, W. Uhl, 1999, Digestion.

Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas

J. Reubi, B. Waser, E. Karamitopoulou, 2015, Modern Pathology.

Old and new peptide receptor targets in cancer: future directions.

J. Reubi, 2013, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications

E. Christ, J. Reubi, D. Wild, 2012, Front. Endocrin..

Strict rules are needed for validation of G-protein-coupled receptor immunohistochemical studies in human tissues

J. Reubi, 2014, Endocrine.

Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance.

J. Laissue, J. Reubi, U. Horisberger, 1997, The Yale journal of biology and medicine.

CRF receptors in the rodent and human cardiovascular systems: Species differences

W. Vale, J. Rivier, J. Reubi, 2006, Peptides.

A novel secretin receptor splice variant potentially useful for early diagnosis of pancreatic carcinoma.

L. Miller, J. Reubi, M. Dong, 2007, Gastroenterology.

Glucagon-like peptide-1 receptor imaging for localization of insulinomas.

F. Forrer, E. Christ, J. Reubi, 2009, The Journal of clinical endocrinology and metabolism.

Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs.

J. Laissue, A. Kappeler, J. Reubi, 1998, Blood.

111In-octreotide scintigraphy in oncology.

E. Krenning, C. V. van Eijck, S. Lamberts, 1992, Metabolism: clinical and experimental.

Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy.

S. Nilsson, J. Laissue, J. Reubi, 1995, Cancer research.

Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.

L. Miller, J. Reubi, P. Portoghese, 2009, Journal of medicinal chemistry.

Somatostatin Receptor 1 Selective Analogues: 2. Nα-Methylated Scan†

D. Hoyer, J. Rivier, J. Reubi, 2005 .

Somatostatin receptors in human prostate and prostate cancer.

J. Reubi, B. Waser, R. Markwalder, 1995, The Journal of clinical endocrinology and metabolism.

Glucagonlike peptide-1 receptor: an example of translational research in insulinomas: a review.

E. Christ, J. Reubi, D. Wild, 2010, Endocrinology and metabolism clinics of North America.

In vivo phosphorylation of the somatostatin 2A receptor in human tumors.

J. Reubi, A. Schonbrunn, Qisheng Liu, 2003, The Journal of clinical endocrinology and metabolism.

Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists.

J. Vaughan, Y. Taché, W. Vale, 2002, Journal of Medicinal Chemistry.

Radiolabelled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues

J. Reubi, B. Waser, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

In Vitro Evaluation of Molecular Tumor Targets in Nuclear Medicine: Immunohistochemistry Is One Option, but Under Which Conditions?

J. Reubi, 2017, The Journal of Nuclear Medicine.

Concomitant vascular GRP-receptor and VEGF-receptor expression in human tumors: Molecular basis for dual targeting of tumoral vasculature

J. Reubi, B. Waser, A. Fleischmann, 2011, Peptides.

Radiotherapeutic for Glucagon-Like Peptide-1Receptor ^ Targeted Therapy for Insulinoma

S. Kneifel, G. Christofori, M. Mihatsch, 2007 .

Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy

S. Schulz, J. Rivier, J. Reubi, 2012, European Journal of Nuclear Medicine and Molecular Imaging.

N-imidazolebenzyl-histidine substitution in somatostatin and in its octapeptide analogue modulates receptor selectivity and function.

J. Rivier, J. Reubi, B. Waser, 2011, Journal of medicinal chemistry.

Conformationally homogeneous heterocyclic pseudotetrapeptides as three-dimensional scaffolds for rational drug design: receptor-selective somatostatin analogues.

John M. Beierle, M. Ghadiri, J. Reubi, 2009, Angewandte Chemie.

Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1).

J. Rivier, J. Reubi, B. Waser, 2001, Journal of medicinal chemistry.

Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth.

B. Evers, J. Reubi, Pomila Singh, 1991, Gastroenterology.

Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging

E. Christ, C. Rottenburger, J. Reubi, 2020, Clinical nuclear medicine.

Somatostatin Receptor Subtype 2A Immunohistochemistry Using a New Monoclonal Antibody Selects Tumors Suitable for In Vivo Somatostatin Receptor Targeting

J. Reubi, B. Waser, M. Körner, 2012, The American journal of surgical pathology.

Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.

F. Forrer, B. Bernard, E. Krenning, 2007, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

64Cu- and 68Ga-labelled [Nle(14),Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats.

P. Nuutila, J. Reubi, M. Béhé, 2014, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

Glucagon-like peptide 1 receptor (GLP-1R) imaging for the preoperative localization of benign insulinomas in 30 patients

P. Ell, F. Forrer, E. Christ, 2012 .

Syntheses, Receptor Bindings, in vitro and in vivo Stabilities and Biodistributions of DOTA‐Neurotensin(8–13) Derivatives Containing β‐Amino Acid Residues – A Lesson about the Importance of Animal Experiments

D. Seebach, B. Kolesińska, J. Reubi, 2013, Chemistry & biodiversity.

Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells.

S. Lamberts, J. Reubi, P. V. van Koetsveld, 1992, Endocrinology.

Genetic changes in somatostatin receptor positive breast tumors

E. Zwarthoff, S. Lamberts, A. Klein, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist

J. Reubi, E. Constable, G. Nicolas, 2018, EJNMMI Research.

Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.

M. Walter, J. Reubi, H. Maecke, 2007, Bioconjugate chemistry.

First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography.

M. Schwaiger, H. Kessler, J. Reubi, 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas.

J. Klijn, J. Jeekel, J. Reubi, 1988, Gastroenterology.

Brunner's Gland Hyperplasia in a Patient after Roux-Y Gastric Bypass: An Important Pitfall in GLP-1 Receptor Imaging

E. Christ, J. Reubi, D. Wild, 2020, Case reports in endocrinology.

Secretin receptor promotes the proliferation of endocrine tumor cells via the PI3K/AKT pathway.

N. Pellegata, J. Reubi, B. Waser, 2012, Molecular endocrinology.

Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients.

E. Christ, C. Stettler, J. Reubi, 2010, The Journal of clinical endocrinology and metabolism.

First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography

Horst Kessler, Margret Schottelius, Markus Schwaiger, 2004, Clinical Cancer Research.

Immunohistochemical detection of somatostatin sst2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: facts and artifacts.

J. Laissue, J. Reubi, B. Waser, 1999, The Journal of clinical endocrinology and metabolism.

Receptor imaging of human diseases using radiolabeled peptides.

E. Krenning, J. Reubi, S. Lamberts, 1995, Journal of receptor and signal transduction research.

Somatostatin and the immune and haematopoetic system; a review

E. Krenning, S. Lamberts, J. Reubi, 1994, European journal of clinical investigation.

Somatostatin receptors as markers for endocrine tumors.

J. Reubi, 1987, JAMA.

[(99m)Tc]Demomedin C, a radioligand based on human gastrin releasing peptide(18-27): synthesis and preclinical evaluation in gastrin releasing peptide receptor-expressing models.

J. Reubi, B. Nock, T. Maina, 2012, Journal of medicinal chemistry.

High expression of gastrin-releasing peptide receptors in the vascular bed of urinary tract cancers: promising candidates for vascular targeting applications.

J. Reubi, B. Waser, A. Fleischmann, 2009, Endocrine-related cancer.

Gastrin-releasing peptide receptors in normal and neoplastic human uterus: involvement of multiple tissue compartments.

J. Reubi, B. Waser, A. Fleischmann, 2005, The Journal of clinical endocrinology and metabolism.

Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue.

H. Friess, H. Kayed, J. Kleeff, 2003, Gastroenterology.

Visualization of the thymus by substance P receptor scintigraphy in man

T. Visser, E. Krenning, J. Laissue, 1996, European Journal of Nuclear Medicine.

Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study

O. Gratzl, S. Hofer, A. Merlo, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

DOTA‐NOC, A high affinity ligand of the somatostatin receptor subtypes 2, 3 and 5 for radiotherapy

B. Bernard, E. Krenning, M. Jong, 2001 .

Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location.

J. Laissue, J. Reubi, B. Waser, 2000, The Journal of clinical endocrinology and metabolism.

Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels.

J. Laissue, J. Reubi, B. Waser, 1996, Metabolism: clinical and experimental.

Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.

P. Neuhaus, C. Ziske, B. Wiedenmann, 1996, Gut.

Somatostatin receptors in malignant tissues

L. Kvols, E. Krenning, J. Reubi, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation.

J. Mandl, G. Kéri, H. Kessler, 2011, ACS medicinal chemistry letters.

Procholecystokinin as Marker of Human Ewing Sarcomas

J. Rehfeld, F. Nielsen, T. V. Hansen, 2004, Clinical Cancer Research.

CCK2 receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours

L. Miller, J. Reubi, B. Waser, 2009, Journal of cellular and molecular medicine.

Somatostatin receptor subtypes sst1, sst2, sst3 and sst5expression in human pituitary, gastroentero‐pancreatic and mammary tumors

G. Mengod, J. Reubi, B. Waser, 1997 .

Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification.

J. Laissue, J. Reubi, B. Waser, 1996, Cancer research.

Pharmacological identity between somatostatin SS-2 binding sites and SSTR-1 receptors.

D. Hoyer, J. Reubi, H. Lübbert, 1995, European journal of pharmacology.

Persistent Lack of Somatostatin of Healing Ulcers in Rats

J. Reubi, B. Waser, A. Schmassmann, 1994 .

Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptidic vector and somatostatin analogue [90Y]-DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC).

S. Hofer, A. Merlo, J. Reubi, 2001, Swiss medical weekly.

Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.

J. Rivier, J. Reubi, B. Waser, 2010, Molecular endocrinology.

Correlative study on neuro‐endocrine differentiation and presence of somatostatin receptors in breast carcinomas

M. Papotti, J. Reubi, G. Bussolati, 1989, International journal of cancer.

Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta.

U. Studer, J. Laissue, J. Reubi, 1993, The Journal of clinical endocrinology and metabolism.

Approaches to improve metabolic stability of a statine-based GRP receptor antagonist.

P. Meyer, J. Reubi, B. Waser, 2017, Nuclear medicine and biology.

Chapter 75 – Somatostatin/NPY

J. Reubi, M. Körner, M. Körner, 2013 .

Somatostatin and NPY

J. Reubi, M. Körner, 2006 .

Cellular detection of sst2A receptors in human gastrointestinal tissue

A. Kappeler, J. Reubi, M. Gugger, 2004, Gut.

Immunohistochemical Localization of Somatostatin Receptor sst2A in Human Gut and Lung Tissue: Possible Implications for Physiology and Carcinogenesis

A. Kappeler, J. Reubi, M. Gugger, 2004, Annals of the New York Academy of Sciences.

Chemical Structure, Pharmacodynamic Profile and Pharmacokinetics of SMS 201–995 (Sandostatin ® )

K. Buchheit, J. Reubi, M. Azria, 1988 .

Running title : Analog regulation of sst 2 signaling and endocytosis

J. Rivier, J. Reubi, R. Cescato, 2005 .

Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors.

J. Reubi, B. Waser, D. Fourmy, 2012, The Journal of clinical endocrinology and metabolism.

Somatostatin and the concept of peptide receptor scintigraphy in oncology.

E. Krenning, S. Lamberts, J. Reubi, 1994, Seminars in oncology.

Somatostatin analogs in the treatment of acromegaly.

E. Krenning, S. Lamberts, J. Reubi, 1992, Endocrinology and metabolism clinics of North America.

In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas.

S. Khosla, L. Kvols, E. Krenning, 1992, The Journal of clinical endocrinology and metabolism.

New specific radioligand for one subpopulation of brain somatostatin receptors.

J. Reubi, 1985, Life sciences.

Value of the radiolabelled GLP-1 receptor antagonist exendin(9–39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans

J. Reubi, B. Waser, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

Classified Histologically as Benign

A. Raabe, N. Cihoric, J. Reubi, 2012 .

Neurokinin-1 Receptor Expression and Its Potential Effects on Tumor Growth in Human Pancreatic Cancer

H. Friess, M. Büchler, M. Korc, 2003, Laboratory Investigation.

Somatostatin analogue scintigraphy in granulomatous diseases

E. Krenning, J. Reubi, D. Kwekkeboom, 1994, European Journal of Nuclear Medicine.

Somatostatin receptor imaging in the diagnosis and treatment of neuroendocrine tumors

E. Krenning, S. Lamberts, J. Reubi, 1992, The Journal of Steroid Biochemistry and Molecular Biology.

A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth.

J. Reubi, 1985, Acta endocrinologica.

Pituitary somatostatin receptors: dissociation at the pituitary level of receptor affinity and biological activity for selective somatostatin analogs

W. Vale, J. Rivier, J. Reubi, 1982, Regulatory Peptides.

Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog

J. Rivier, J. Reubi, B. Waser, 2010, European Journal of Nuclear Medicine and Molecular Imaging.

and Substance P in Distinct Compartments of Human Lymphoid Organs Localization of Receptors for Vasoactive Intestinal Peptide, Somatostatin,

J. Laissue, A. Kappeler, J. Reubi, 2009 .

Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas.

B. Scheithauer, L. Jin, X. Qian, 1998, The American journal of pathology.

Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer

J. Foekens, J. Klijn, H. Portengen, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

Wild-type and splice-variant secretin receptors in lung cancer: overexpression in carcinoid tumors and peritumoral lung tissue

L. Miller, J. Reubi, M. Körner, 2008, Modern Pathology.

Somatostatin receptor imaging in vivo by planar scintigraphy facilitates the diagnosis of canine insulinomas.

J. Reubi, S. McDonough, O. Garden, 2005, Journal of veterinary internal medicine.

Octreotide: an active agent in epithelial ovarian carcinoma?

P. Vasey, J. Reubi, D. Millan, 2004, The Lancet. Oncology.

Somatostatin (SRIH) messenger ribonucleic acid expression in human neuroendocrine and brain tumors using in situ hybridization histochemistry: comparison with SRIH receptor content.

G. Mengod, J. Reubi, B. Waser, 1993, The Journal of clinical endocrinology and metabolism.

Somatostatin receptors in differentiated ovarian tumors.

J. Foekens, J. Klijn, J. Reubi, 1991, The American journal of pathology.

Tumors: In Vitro Identification

J. Laissue, J. Reubi, B. Waser, 1996 .

Vasoactive intestinal peptide (VIP) and VIP receptors: Gene expression and growth modulation in medulloblastoma and other central primitive neuroectodermal tumors of childhood

T. Pietsch, M. Frühwald, J. Reubi, 1999, International journal of cancer.

Vasoactive Intestinal Peptide / Pituitary Adenylate Cyclase-activating Peptide Receptor Subtypes in Human Tumors and Their Tissues of Origin 1

J. Laissue, J. Reubi, P. Robberecht, 2000 .

Slaging of Sézary syndrome with somatostatin receptor scintigraphy

E. Krenning, J. Reubi, F. Heule, 1996, The British journal of dermatology.

Design, synthesis, and biological evaluation of somatostatin-based radiopeptides.

S. Schulz, M. de Jong, J. Reubi, 2006, Chemistry & biology.

One-step ¹⁸F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET).

K. Jurkschat, P. Bartenstein, H. Buchholz, 2010, Bioconjugate chemistry.

Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity.

R. Riek, J. Rivier, J. Reubi, 2008, Journal of medicinal chemistry.

Novel sst5-selective somatostatin dicarba-analogues: synthesis and conformation-affinity relationships.

E. Novellino, A. Carotenuto, M. Ginanneschi, 2008, Journal of medicinal chemistry.

Glutamate release in vitro from corticostriatal terminals

M. Cuénod, J. Reubi, M. Cuénod, 1979, Brain Research.

On the Terminal Homologation of Physiologically Active Peptides as a Means of Increasing Stability in Human Serum – Neurotensin, Opiorphin, B27‐KK10 Epitope, NPY

M. Ebert, D. Seebach, J. Reubi, 2011, Chemistry & biodiversity.

Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.

J. Rivier, J. Reubi, B. Waser, 2003, Journal of medicinal chemistry.

High Expression of Neuropeptide Y1 Receptors in Ewing Sarcoma Tumors

J. Reubi, B. Waser, M. Körner, 2008, Clinical Cancer Research.

NPY receptors in human cancer: A review of current knowledge

J. Reubi, M. Körner, Jean Claude Reubi, 2007, Peptides.

Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas

J. Reubi, B. Waser, M. Körner, 2005, International journal of cancer.

Neuropeptide Y receptor expression in human primary ovarian neoplasms

J. Reubi, B. Waser, M. Körner, 2004, Laboratory Investigation.

Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets.

J C Reubi, J. Reubi, M. Gugger, 2001, Cancer research.

Targeting GRPR in urological cancers—from basic research to clinical application

J. Reubi, R. Mansi, A. Fleischmann, 2013, Nature Reviews Urology.

In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging.

J C Reubi, J. Reubi, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Asparagine as Precursor for Transmitter Aspartate in Corticostriatal Fibres

M. Cuénod, J. Reubi, G. Toggenburger, 1980, Journal of neurochemistry.

Comparative study of the release of glutamate and GABA, newly synthesized from glutamine, in various regions of the central nervous system

J. Reubi, J.-C. Reubi, 1980, Neuroscience.

The effect of cochlear nerve lesion on the release of glutamate, aspartate, and GABA from cat cochlear nucleus, in vitro

J. Reubi, V. Čanžek, 2004, Experimental Brain Research.

Peptide receptor expression in GEP-NET

J. Reubi, 2007, Virchows Archiv.

Three‐year recurrence‐free survival in a patient with recurrent medulloblastoma after resection, high‐dose chemotherapy, and intrathecal Yttrium‐90‐labeled DOTA0‐D‐Phe1‐Tyr3‐octreotide radiopeptide brachytherapy

A. Merlo, J. Reubi, T. Kühne, 2005, Cancer.

Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors.

J C Reubi, J. Reubi, B. Waser, 1997, Cancer research.

Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan.

J. Rivier, J. Reubi, B. Waser, 2003, Journal of medicinal chemistry.

Gigantism due to pituitary mammosomatotroph hyperplasia.

S. Asa, K. Kovacs, J. Reubi, 1990, The New England journal of medicine.

High expression of peptide receptors as a novel target in gastrointestinal stromal tumours

L. Mazzucchelli, L. Guillou, J. Reubi, 2004, European Journal of Nuclear Medicine and Molecular Imaging.

Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.

J C Reubi, J. Laissue, J. Reubi, 2000, Cancer research.

Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting

Anastasia Nikolopoulou, J. Reubi, B. Nock, 2008, Journal of Nuclear Medicine.

GPR 87 is an overexpressed G-protein coupled receptor in squamous cell carcinoma of the lung

R. White, J. Reubi, M. Gugger, 2014 .

GPR87 Is an Overexpressed G-Protein Coupled Receptor in Squamous Cell Carcinoma of the Lung

R. White, J. Reubi, M. Gugger, 2007, Disease markers.

Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.

E. Krenning, J. Reubi, D. Kwekkeboom, 2010, Gastroenterology.

Unexpected high incidence of cholecystokinin‐B/gastrin receptors in human medullary thyroid carcinomas

J C Reubi, J. Reubi, B. Waser, 1996, International journal of cancer.

High gastrin and cholecystokinin (CCK) gene expression in human neuronal, renal, and myogenic stem cell tumors: comparison with CCK-A and CCK-B receptor contents.

J. Reubi, J. Schaer, J. Reubi, 1999, The Journal of clinical endocrinology and metabolism.

GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting

J. Reubi, B. Waser, M. Körner, 2007, Journal of Nuclear Medicine.

Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer.

J. Foekens, J. Klijn, H. Portengen, 1989, Cancer research.

Neuropeptide Y modulates steroid production of human adrenal H295R cells through Y1 receptors

J. Reubi, C. Flück, M. Körner, 2010, Molecular and Cellular Endocrinology.

Specific luteinizing-hormone-releasing hormone receptor binding sites in hippocampus and pituitary: an autoradiographical study

J. Palacios, J. Reubi, R. Maurer, 1987, Neuroscience.

Visualization of LHRH receptors in the rat brain.

J. Reubi, R. Maurer, 1984, European journal of pharmacology.

Distribution and coregulation of three peptide receptors in adrenals.

J. Reubi, R. Maurer, 1986, European journal of pharmacology.

Overexpression of Gastrin-Releasing Peptide Receptors in Tumor-Associated Blood Vessels of Human Ovarian Neoplasms

J. Reubi, B. Waser, A. Fleischmann, 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

Distribution of the VPAC2 receptor in peripheral tissues of the mouse.

A. Harmar, W. Sheward, C. Morrison, 2004, Endocrinology.

The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors

J. Foekens, J. Klijn, S. Lamberts, 1990, Breast Cancer Research and Treatment.

Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia.

H. Friess, L. Miller, J. Reubi, 2005, The American journal of pathology.

Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).

J. Reubi, Hanwen Zhang, F. Bruchertseifer, 2011, Cancer research.

Lu-DOTA-PESIN ) 177 Bi-AMBA versus 213 Bi-DOTA-PESIN and 213 Human Prostate Cancer Model ( Alpha-versus Beta-Particle Radiopeptide Therapy in a Updated

J. Reubi, Hanwen Zhang, F. Bruchertseifer, 2011 .

Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model.

J. Reubi, B. Waser, H. Maecke, 2010, European journal of pharmacology.

New Pansomatostatin Ligands and Their Chelated Versions: Affinity Profile, Agonist Activity, Internalization, and Tumor Targeting

S. Schulz, J. Reubi, Hanwen Zhang, 2008, Clinical Cancer Research.

Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy.

J C Reubi, J. Reubi, 1997, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors.

E. Novellino, D. Brancaccio, A. Carotenuto, 2010, Journal of medicinal chemistry.

Highly Increased 125I-JR11 Antagonist Binding In Vitro Reveals Novel Indications for sst2 Targeting in Human Cancers

J. Rivier, J. Reubi, B. Waser, 2017, The Journal of Nuclear Medicine.

PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference

Wolfgang A Weber, W. Weber, J. Reubi, 2011, The Journal of Nuclear Medicine.

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

Judit Erchegyi, J. Rivier, J. Reubi, 2006, Proceedings of the National Academy of Sciences.

Candidates for peptide receptor radiotherapy today and in the future.

E. Krenning, J. Reubi, Jean Claude Reubi, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting

J. Reubi, M. Gugger, B. Waser, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors.

E. Krenning, F. Bosman, C. V. van Eijck, 1996, Annals of surgery.

Persistent lack of somatostatin receptors in gastric mucosa of healing ulcers in rats.

J. Reubi, B. Waser, F. Halter, 1994, Gastroenterology.

Somatostatin receptor‐positive primary breast tumors: Genetic, patient and tumor characteristics

J. Foekens, E. Zwarthoff, C. V. van Eijck, 1993, International journal of cancer.

The Role of Somatostatin Receptors in the Diagnosis and Therapy of Cancer

E. Krenning, J. Reubi, S. W. Lambert, 1993 .

Distribution of somatostatin receptors in the human brain: An autoradiographic study

J. Palacios, R. Cortės, A. Probst, 1986, Neuroscience.

Peptide-Based Probes for Cancer Imaging

J. Reubi, H. Maecke, Jean Claude Reubi, 2008, Journal of Nuclear Medicine.

High Expression of Somatostatin Receptor Subtype 2 (sst2) in Medulloblastoma: Implications for Diagnosis and Therapy

T. Pietsch, M. Frühwald, J. Reubi, 1999, Pediatric Research.

Glucagon-like peptide 1-receptor scans to localize occult insulinomas.

Emanuel Christ, E. Christ, J. Reubi, 2008, The New England journal of medicine.

Triple-Peptide Receptor Targeting In Vitro Allows Detection of All Tested Gut and Bronchial NETs

J. Reubi, B. Waser, 2015, The Journal of Nuclear Medicine.

Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

J. Reubi, B. Waser, Jean Claude Reubi, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Local up-regulation of neuropeptide receptors in host blood vessels around human colorectal cancers.

L. Mazzucchelli, J. Laissue, J. Reubi, 1996, Gastroenterology.

Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer.

I. Smith, J. Reubi, V. Macaulay, 1991, British Journal of Cancer.

[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.

Martin Gotthardt, Andreas Wicki, Boris Keil, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A possible role for somatostatin receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma

M. Frühwald, J. Reubi, M. Warmuth-Metz, 1998, Journal of Neuro-Oncology.

Somatostatin receptors in normal and tumoral tissue.

J. Reubi, S. Lamberts, R. Maurer, 1988, Hormone research.

Nonketotic hyperglycinemia treated with strychnine, a glycine receptor antagonist.

M. Cuénod, G. Dumermuth, M. Herdan, 1978, Helvetica paediatrica acta.

111In-octreotide scintigraphy in oncology.

E. Krenning, C. V. van Eijck, S. Lamberts, 1993, Digestion.

Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide.

T. Visser, E. Krenning, S. Lamberts, 1994, Seminars in oncology.

Neurotensin receptors in human neoplasms: High incidence in Ewing's sarcomas

J. Laissue, J. Reubi, B. Waser, 1999, International journal of cancer.

The intestinal immune system and its relation to disease.

J. Laissue, J. Reubi, J. Gebbers, 1993, Digestive diseases.

[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor–Targeted Therapy for Insulinoma

S. Kneifel, G. Christofori, M. Mihatsch, 2007, Clinical Cancer Research.

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors

P. Ell, P. Benkert, J. Reubi, 2013, The Journal of Nuclear Medicine.

PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors

P. Ell, P. Benkert, J. Reubi, 2013 .

Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.

G. Mengod, J. Reubi, B. Waser, 1997, International journal of cancer.

Immunocytochemistry of pituitary tumors.

M. Oberholzer, J. Reubi, P. Heitz, 1987, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Analgesic activity of a non-peptide imidazolidinedione somatostatin agonist: In vitro and in vivo studies in rat

J. Reubi, S. Carlton, G. Ji, 2006, Pain.

gastric and colonic smooth muscle cells Expression of somatostatin receptor subtypes on guinea pig

R. Jensen, M. Hauer-Jensen, J. Rivier, 2011 .

Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment

M. Bidlingmaier, L. Frohman, J. Reubi, 2007, Pituitary.

Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.

Martin A Walter, M. Walter, J. Reubi, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study

J. Rivier, J. Reubi, M. Lassmann, 2017, The Journal of Nuclear Medicine.

Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients.

E. Christ, J. Reubi, B. Waser, 2012, The American journal of pathology.

Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor.

M. Grant, J. Reubi, S. Caballero, 2008, Investigative ophthalmology & visual science.

Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.

Jean E Rivier, J. Rivier, J. Reubi, 2008, Journal of medicinal chemistry.

PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide

M. Schwaiger, K. Scheidhauer, J. Reubi, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.

E P Krenning, J C Reubi, T. Visser, 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.

B. Bernard, E. Krenning, W. Breeman, 2006, European journal of nuclear medicine and molecular imaging.

Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides.

J. Rivier, J. Reubi, B. Waser, 2005, Journal of medicinal chemistry.

Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan.

D. Hoyer, J. Rivier, J. Reubi, 2005, Journal of medicinal chemistry.

[111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?

W. Wiersinga, E. Krenning, J. Reubi, 1994, The Journal of clinical endocrinology and metabolism.

Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake

A. Devillers, J. Reubi, P. Bourguet, 1998, European Journal of Nuclear Medicine.

Somatostatin receptor scintigraphy in non-medullary thyroid cancer.

H. van Toor, E. Krenning, J. Reubi, 1996, Digestion.

Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues.

R. Riek, D. Hoyer, J. Rivier, 2009, Journal of medicinal chemistry.

Octreotide and Related Somatostatin Analogs in the Diagnosis and Treatment of Pituitary Disease and Somatostatin Receptor Scintigraphy

E. Krenning, S. Lamberts, J. Reubi, 1993, Frontiers in Neuroendocrinology.

Value of Immunohistochemistry for Somatostatin Receptor Subtype sst2A in Cancer Tissues: Lessons From the Comparison of Anti-sst2A Antibodies With Somatostatin Receptor Autoradiography

J. Reubi, B. Waser, M. Körner, 2005, The American journal of surgical pathology.

Targeting CCK receptors in human cancers.

J. Reubi, Jean Claude Reubi, 2007, Current topics in medicinal chemistry.

Regulation of GABA release by dopamine in the rat substantia nigra.

L. Iversen, T. Jessell, J. Reubi, 1978, Advances in biochemical psychopharmacology.

Neurotensin receptors in pancreatic ductal carcinomas

M. Büchler, J. Reubi, B. Waser, 2015, EJNMMI Research.

Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma

J C Reubi, H. Friess, J. Laissue, 1998, Gut.

Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.

P. Ell, F. Forrer, E. Christ, 2013, The lancet. Diabetes & endocrinology.

PET/CT Imaging of Unstable Carotid Plaque with 68Ga-Labeled Somatostatin Receptor Ligand

T. Richards, S. Michopoulou, R. Shortman, 2017, The Journal of Nuclear Medicine.

Radionuclide Therapy : A Pilot Study Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor

W. Weber, J. Reubi, D. Wild, 2014 .

Evaluation of somatostatin analogues for the detection and treatment of gastrinoma in a dog.

M Altschul, J C Reubi, J. Cummings, 1997, The Journal of small animal practice.

The relationship between somatostatin, epidermal growth factor, and steroid hormone receptors in breast cancer

J. Reubi, Jean‐Claude Reubi, Joachim Torhorst, 1989, Cancer.

Expression of CRF1 and CRF2 receptors in human cancers.

W. Vale, J. Rivier, J. Reubi, 2003, The Journal of clinical endocrinology and metabolism.

A new and sensitive staining method for axonally transported horseradish peroxidase (HRP) in the pigeon visual system

P. Streit, J. Reubi, 1977, Brain Research.

EGF receptors in human breast cancer on viable and necrotic tumour cells

J. Reubi, J. Torhorst, 1988, Breast Cancer Research and Treatment.

Effects of gonadotropin-releasing hormone and its agonists on prolactin secretion from normal and tumorous pituitary cells.

S. Lamberts, F. de Jong, J. Reubi, 1989, Neuroendocrinology.

Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours

F. Forrer, J. Reubi, R. Mansi, 2010, European Journal of Nuclear Medicine and Molecular Imaging.

Dopamine selectively increases 3H-GABA release from slices of rat substantia nigra in vitro

L. Iversen, T. Jessell, J. Reubi, 1977, Nature.

Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome.

E. Krenning, S. Lamberts, J. Reubi, 1994, Digestion.

Use of Betidamino Acids in Drug Design

R. Riek, J. Rivier, J. Reubi, 2006 .

Use of isotope-labeled somatostatin analogs for visualization of islet cell tumors

E. Krenning, S. Lamberts, J. Reubi, 1993, World Journal of Surgery.

Somatostatin receptors in nasopharyngeal carcinoma

J. Reubi, B. Waser, K. Loh, 2002, Virchows Archiv.

Positive somatostatin receptorscintigraphy correlates withthepresenceofsomatostatin receptorsubtype 2

B. Wiedenmann, H. Scherübl, W. Meyerhof, 1996 .

Validation of somatostatin receptor scintigraphy in the localization of neuroendocrine tumors.

E. Krenning, S. Lamberts, J. Reubi, 1993, Acta oncologica.

Somatostatin receptors in GtoPdb v.2023.1

D. Hoyer, S. Schulz, S. Melmed, 2023, IUPHAR/BPS Guide to Pharmacology CITE.

Localization of Hidden Insulinomas with 68Ga-DOTA-Exendin-4 PET/CT: A Pilot Study

E. Christ, C. Rottenburger, J. Reubi, 2015, The Journal of Nuclear Medicine.

Somatostatin‐receptor Scintigraphy in Gastroenteropancreatic Tumors

E. Krenning, S. Lamberts, J. Reubi, 1994, Annals of the New York Academy of Sciences.

Somatostatin receptor 1 selective analogues: 4. Three-dimensional consensus structure by NMR.

R. Riek, J. Rivier, J. Reubi, 2005, Journal of medicinal chemistry.

Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial

A. Merlo, F. Forrer, J. Reubi, 2010, European Journal of Nuclear Medicine and Molecular Imaging.

Absence of somatostatin receptors in psoriatic skin lesions

J. Reubi, T. Hunziker, 2004, Archives of Dermatological Research.

Molecular imaging of bombesin receptors in various tumors by Ga-68 AMBA PET/CT: First results

V. Prasad, R. Baum, J. Reubi, 2007 .

Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting.

M. Hennig, J. Reubi, T. Kaden, 2008, Chemistry.

Selective bidirectional transport of [3H]d-aspartate in the pigeon retino-tectal pathway

A. Beaudet, A. Burkhalter, M. Cuénod, 1981, Neuroscience.

Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours

E. Krenning, M. Jong, J. Erion, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats.

J. Reubi, A. Lázníčková, M. Lázníček, 2010, Anticancer research.

Expression of somatostatin receptors in childhood neuroblastoma.

D. Schaid, B. Scheithauer, L. Kvols, 1994, American journal of clinical pathology.

Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours.

S. Lamberts, J. Reubi, G. Pieters, 1988, Acta endocrinologica.

Diurnal variation in the release of alpha-MSH from rat hypothalamus and pituitary.

J. Reubi, A. Eberle, W. Lichtensteiger, 1981, Neuroendocrinology.

Clinical relevance of somatostatin receptor imaging.

J. Reubi, 1994, European Journal of Endocrinology.

Lys 40 ( Ahx-DTPA-111 In ) NH 2 ]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor ^ TargetedTherapy for

S. Kneifel, G. Christofori, M. Mihatsch, 2007 .

VIP analogues inhibit small cell lung cancer growth

T. Moody, I. Gozes, J. Reubi, 1992 .

Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients.

Franz Buchegger, J. Reubi, F. Buchegger, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Transmitter-specific retrograde tracing of pathways?

M. Cuénod, P. Streit, J. Reubi, 1979, Progress in brain research.

Kainic acid toxicity and binding in the optic tectum.

M. Cuénod, P. Streit, J. Reubi, 1979, Progress in brain research.

Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc.

J. Reubi, D. Tourwé, B. Nock, 2006, Journal of Medicinal Chemistry.

New Gastrin Releasing Peptide Receptor-Directed [99mTc]Demobesin 1 Mimics: Synthesis and Comparative Evaluation.

J. Reubi, G. Nicolas, B. Nock, 2018, Journal of medicinal chemistry.

Erratum to: 64Cu- and 68Ga-Labelled [Nle14,Lys40(Ahx-NODAGA)NH2]-Exendin-4 for Pancreatic Beta Cell Imaging in Rats

P. Nuutila, J. Reubi, M. Béhé, 2013, Molecular Imaging and Biology.

Erratum: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors (Neuroendocrinology (2004) 80 (394-424))

E. Krenning, B. Wiedenmann, R. Arnold, 2005 .

First clinical evaluation of somatostatin receptor antagonist imaging

W. Weber, J. Rivier, J. Reubi, 2010 .

Somatostatin and Thyrotrophin‐Releasing Hormone Response and Receptor Status of a Thyrotrophin‐Secreting Pituitary Adenoma: Clinical and in vitro Studies

D. Eckland, S. Lightman, J. Reubi, 1989, Journal of neuroendocrinology.

Effects of GABA, dopamine, and substance P on the release of newly synthesized 3H-5-hydroxytryptamine from rat substantia nigra in vitro

T. Jessell, J. Reubi, P. Emson, 1978, Naunyn-Schmiedeberg's Archives of Pharmacology.

GIP receptor: Expression in neuroendocrine tumours, internalization, signalling from endosomes and structure-function relationship studies

J. Reubi, I. Tikhonova, D. Fourmy, 2019, Peptides.

Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: Relationship to egf receptors

J. Foekens, J. Klijn, J. Laissue, 1990, International journal of cancer.

Mass fragmentographic determination of endogenous glycine and glutamic acid released in vivo from the pigeon optic tectum. Effect of electric stimulation of a midbrain nucleus

J. Reubi, M. Wolfensberger, U. Redweik, 1981, Brain Research.

Highly potent 4-amino-indolo[2,3-c]azepin-3-one-containing somatostatin mimetics with a range of sst receptor selectivities.

J. Reubi, D. Tourwé, R. Cescato, 2009, Journal of medicinal chemistry.

Glucagon-like peptide-1 vs. somatostatin receptor targeting in malignant insulinoma

P. Ell, E. Christ, J. Reubi, 2010 .

Octreotide and octreotate derivatives radiolabeled with yttrium: pharmacokinetics in rats.

J. Reubi, S. Wenger, A. Lázníčková, 2002, Cancer biotherapy & radiopharmaceuticals.

Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity.

R. Riek, J. Rivier, J. Reubi, 2008, Journal of medicinal chemistry.

HORMONE DEPENDENCY OF MENINGIOMAS

J. Reubi, S. Lamberts, J. Palacios, 1989, The Lancet.

Three-dimensional consensus structure of sst2-selective somatostatin (SRIF) antagonists by NMR.

R. Riek, J. Rivier, J. Reubi, 2008, Biopolymers.

Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR.

R. Riek, J. Rivier, J. Reubi, 2003, Journal of medicinal chemistry.

Lack of evidence for cross-competition between vasoactive intestinal peptide and somatostatin at their respective receptors.

D. Hoyer, J. Reubi, B. Waser, 2001, European journal of pharmacology.

The role of somatostatin analogs in the control of tumor growth.

E. Krenning, S. Lamberts, J. Reubi, 1994, Seminars in Oncology.

A rare localization of a neuroendocrine tumor.

C. Stettler, J. Reubi, M. Stalder, 2011, The Journal of clinical endocrinology and metabolism.

Preoperative localization of adult nesidioblastosis using 68Ga-DOTA-exendin-4-PET/CT

E. Christ, J. Reubi, T. Heye, 2015, Endocrine.

Somatostatin receptors in schwannomas.

J. Reubi, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

New Pansomatostatin Ligands and Their Chelated Versions: Affinity Profile, Agonist Activity, Internalization, and Tumor Targeting

S. Schulz, J. Reubi, Hanwen Zhang, 2008, Clinical Cancer Research.

In Vitro Identification of VIP Receptors in Human Tumors: Potential Clinical Implications

J. Reubi, 1996, Annals of the New York Academy of Sciences.

PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference

W. Weber, J. Reubi, R. Mansi, 2011, The Journal of Nuclear Medicine.

Glutamatergic pathways in the pigeon and the rat brain.

A. Beaudet, M. Cuénod, P. Streit, 1981, Advances in biochemical psychopharmacology.

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

T. Visser, E. Krenning, M. Jong, 1993, European Journal of Nuclear Medicine.

Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours

B. Wiedenmann, P. Ruszniewski, J. Reubi, 2004, Neuroendocrinology.

PET/CT: A Pilot Study

E. Christ, C. Rottenburger, J. Reubi, 2015 .

Bombesin Antagonist–Based Radioligands for Translational Nuclear Imaging of Gastrin-Releasing Peptide Receptor–Positive Tumors

F. Forrer, J. Reubi, G. Nicolas, 2011, The Journal of Nuclear Medicine.

Biochemical Neuroanatomy of the Pigeon Optic Tectum

S. Hunt, H. Künzle, M. Cuénod, 1976 .

[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.

B. Keil, G. Christofori, A. Wicki, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.